- Discover Astex
- R&D
- Clinical Pipeline
- Partnered Products and Programs
- Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap® PKB/Akt Inhibitor (Oncology)
- KRAS Oncogene (Oncology)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- SHP2 (Oncology)
- P53 tumour suppressor protein (Oncology)
- Proprietary Products and Programs
- Partnered Products and Programs
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation Postdocs
- Clinical Pipeline
- Partnering
- Our People & Culture
- Media
- Contact
© Astex Pharmaceuticals
All rights reserved
